BACKGROUND & AIMS: Progressive familial intrahepatic cholestasis (PFIC) with normal serum levels of gamma-glutamyltranspeptidase can result from mutations in ATP8B1 (encoding familial intrahepatic cholestasis 1 [FIC1]) or ABCB11 (encoding bile salt export pump [BSEP]). We evaluated clinical and laboratory features of disease in patients diagnosed with PFIC, who carried mutations in ATP8B1 (FIC1 deficiency) or ABCB11 (BSEP deficiency). Our goal was to identify features that distinguish presentation and course of these two disorders, thus facilitating diagnosis and elucidating the differing consequences of ATP8B1 and ABCB11 mutations. METHODS: A retrospective multi-center study was conducted, using questionnaires and chart review. Available clinical and biochemical data from 145 PFIC patients with mutations in either ATP8B1 (61 "FIC1 patients") or ABCB11 (84 "BSEP patients") were evaluated. RESULTS: At presentation, serum aminotransferase and bile salt levels were higher in BSEP patients; serum alkaline phosphatase values were higher, and serum albumin values were lower, in FIC1 patients. Elevated white blood cell counts, and giant or multinucleate cells at liver biopsy, were more common in BSEP patients. BSEP patients more often had gallstones and portal hypertension. Diarrhea, pancreatic disease, rickets, pneumonia, abnormal sweat tests, hearing impairment, and poor growth were more common in FIC1 patients. Among BSEP patients, the course of disease was less rapidly progressive in patients bearing the D482G mutation. CONCLUSIONS: Severe forms of FIC1 and BSEP deficiency differed. BSEP patients manifested more severe hepatobiliary disease, while FIC1 patients showed greater evidence of extrahepatic disease. Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
BACKGROUND & AIMS: Progressive familial intrahepatic cholestasis (PFIC) with normal serum levels of gamma-glutamyltranspeptidase can result from mutations in ATP8B1 (encoding familial intrahepatic cholestasis 1 [FIC1]) or ABCB11 (encoding bile salt export pump [BSEP]). We evaluated clinical and laboratory features of disease in patients diagnosed with PFIC, who carried mutations in ATP8B1 (FIC1 deficiency) or ABCB11 (BSEP deficiency). Our goal was to identify features that distinguish presentation and course of these two disorders, thus facilitating diagnosis and elucidating the differing consequences of ATP8B1 and ABCB11 mutations. METHODS: A retrospective multi-center study was conducted, using questionnaires and chart review. Available clinical and biochemical data from 145 PFICpatients with mutations in either ATP8B1 (61 "FIC1patients") or ABCB11 (84 "BSEPpatients") were evaluated. RESULTS: At presentation, serum aminotransferase and bile salt levels were higher in BSEPpatients; serum alkaline phosphatase values were higher, and serum albumin values were lower, in FIC1patients. Elevated white blood cell counts, and giant or multinucleate cells at liver biopsy, were more common in BSEPpatients. BSEPpatients more often had gallstones and portal hypertension. Diarrhea, pancreatic disease, rickets, pneumonia, abnormal sweat tests, hearing impairment, and poor growth were more common in FIC1patients. Among BSEPpatients, the course of disease was less rapidly progressive in patients bearing the D482G mutation. CONCLUSIONS: Severe forms of FIC1 and BSEP deficiency differed. BSEPpatients manifested more severe hepatobiliary disease, while FIC1patients showed greater evidence of extrahepatic disease. Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Authors: A S Knisely; Sandra S Strautnieks; Yvonne Meier; Bruno Stieger; Jane A Byrne; Bernard C Portmann; Laura N Bull; Ludmila Pawlikowska; Banu Bilezikçi; Figen Ozçay; Aranka László; László Tiszlavicz; Lynette Moore; Jeremy Raftos; Henrik Arnell; Björn Fischler; Antal Németh; Nikos Papadogiannakis; Joanna Cielecka-Kuszyk; Irena Jankowska; Joanna Pawłowska; Hector Melín-Aldana; Karan M Emerick; Peter F Whitington; Giorgina Mieli-Vergani; Richard J Thompson Journal: Hepatology Date: 2006-08 Impact factor: 17.425
Authors: Jacqueline R M Plass; Olaf Mol; Janette Heegsma; Mariska Geuken; Joost de Bruin; Geeske Elling; Michael Müller; Klaas Nico Faber; Peter L M Jansen Journal: J Hepatol Date: 2004-01 Impact factor: 25.083
Authors: Leo W J Klomp; Julie C Vargas; Saskia W C van Mil; Ludmila Pawlikowska; Sandra S Strautnieks; Michiel J T van Eijk; Jenneke A Juijn; Carlos Pabón-Peña; Lauren B Smith; Joseph A DeYoung; Jane A Byrne; Justijn Gombert; Gerda van der Brugge; Ruud Berger; Irena Jankowska; Joanna Pawlowska; Erica Villa; A S Knisely; Richard J Thompson; Nelson B Freimer; Roderick H J Houwen; Laura N Bull Journal: Hepatology Date: 2004-07 Impact factor: 17.425
Authors: P J Kaliciński; H Ismail; I Jankowska; A Kamiński; J Pawłowska; T Drewniak; M Markiewicz; M Szymczak Journal: Eur J Pediatr Surg Date: 2003-10 Impact factor: 2.191
Authors: Frank Chen; M Ananthanarayanan; Sukru Emre; Ezequiel Neimark; Laura N Bull; A S Knisely; Sandra S Strautnieks; Richard J Thompson; Margret S Magid; Ronald Gordon; N Balasubramanian; Frederick J Suchy; Benjamin L Shneider Journal: Gastroenterology Date: 2004-03 Impact factor: 22.682
Authors: Kimberley Evason; Kevin E Bove; Milton J Finegold; A S Knisely; Sue Rhee; Philip Rosenthal; Alexander G Miethke; Saul J Karpen; Linda D Ferrell; Grace E Kim Journal: Am J Surg Pathol Date: 2011-05 Impact factor: 6.394
Authors: Cindy Kunne; Marijke de Graaff; Suzanne Duijst; Dirk R de Waart; Ronald P J Oude Elferink; Coen C Paulusma Journal: Lab Invest Date: 2014-07-28 Impact factor: 5.662
Authors: Sohela Shah; Ukina R Sanford; Julie C Vargas; Hongmei Xu; Annamiek Groen; Coen C Paulusma; James P Grenert; Ludmila Pawlikowska; Saunak Sen; Ronald P J Oude Elferink; Laura N Bull Journal: PLoS One Date: 2010-02-01 Impact factor: 3.240